132 related articles for article (PubMed ID: 37804754)
1. Chronic myeloid leukaemia: A qualitative interview study exploring disease impact from patient and practitioner perspectives.
Hewison A; Roman E; Smith A; McCaughan D; Sheridan R; Patmore R; Atkin K; Howell D
Eur J Oncol Nurs; 2023 Dec; 67():102421. PubMed ID: 37804754
[TBL] [Abstract][Full Text] [Related]
2. Experiences of living with chronic myeloid leukaemia and adhering to tyrosine kinase inhibitors: A thematic synthesis of qualitative studies.
Hewison A; Atkin K; McCaughan D; Roman E; Smith A; Smith G; Howell D
Eur J Oncol Nurs; 2020 Apr; 45():101730. PubMed ID: 32169687
[TBL] [Abstract][Full Text] [Related]
3. Incurable but treatable: Understanding, uncertainty and impact in chronic blood cancers-A qualitative study from the UK's Haematological Malignancy Research Network.
Howell DA; McCaughan D; Smith AG; Patmore R; Roman E
PLoS One; 2022; 17(2):e0263672. PubMed ID: 35143569
[TBL] [Abstract][Full Text] [Related]
4. Palliative care specialists' perceptions concerning referral of haematology patients to their services: findings from a qualitative study.
McCaughan D; Roman E; Smith AG; Garry AC; Johnson MJ; Patmore RD; Howard MR; Howell DA
BMC Palliat Care; 2018 Feb; 17(1):33. PubMed ID: 29466968
[TBL] [Abstract][Full Text] [Related]
5. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
Kizilors A; Crisà E; Lea N; Passera R; Mian S; Anwar J; Best S; Nicolini FE; Ireland R; Aldouri M; Pocock C; Corbett T; Gale R; Bart-Smith E; Weston-Smith S; Wykes C; Kulasekararaj A; Jackson S; Harrington P; McLornan D; Raj K; Pagliuca A; Mufti GJ; de Lavallade H
Lancet Haematol; 2019 May; 6(5):e276-e284. PubMed ID: 31036317
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
[TBL] [Abstract][Full Text] [Related]
7. Another set of guidelines for chronic myeloid leukaemia.
Clark RE
Br J Haematol; 2020 Oct; 191(2):147-149. PubMed ID: 32712951
[No Abstract] [Full Text] [Related]
8. Experiences and preferences for psychosocial support: a qualitative study exploring the views of patients with chronic haematological cancers.
Sheridan R; McCaughan D; Hewison A; Roman E; Smith A; Patmore R; Howell D
BMJ Open; 2023 Aug; 13(8):e070467. PubMed ID: 37597866
[TBL] [Abstract][Full Text] [Related]
9. Illness uncertainty, self-perceived burden and quality of life in patients with chronic myeloid leukaemia: A cross-sectional study.
Zhang N; Tang XQ; Lu K; Dong Q; Kong LN; Jiang TT; Xu LY
J Clin Nurs; 2022 Oct; 31(19-20):2935-2942. PubMed ID: 34786783
[TBL] [Abstract][Full Text] [Related]
10. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.
Martinelli G; Oehler VG; Papayannidis C; Courtney R; Shaik MN; Zhang X; O'Connell A; McLachlan KR; Zheng X; Radich J; Baccarani M; Kantarjian HM; Levin WJ; Cortes JE; Jamieson C
Lancet Haematol; 2015 Aug; 2(8):e339-46. PubMed ID: 26688487
[TBL] [Abstract][Full Text] [Related]
11. Treatment decision making (TDM): a qualitative study exploring the perspectives of patients with chronic haematological cancers.
McCaughan D; Roman E; Smith A; Patmore R; Howell D
BMJ Open; 2022 Mar; 12(3):e050816. PubMed ID: 35351694
[TBL] [Abstract][Full Text] [Related]
12. Medication experience and patient's related needs in chronic myeloid leukemia treated with tyrosine kinase inhibitors: Systematic review.
Cachafeiro Pin AI; Villaverde Piñeiro L; Martín Clavo S; Silva Castro MM
Farm Hosp; 2023; 47(2):85-92. PubMed ID: 36599752
[TBL] [Abstract][Full Text] [Related]
13. Changing causes of death in persons with haematological cancers 1975-2016.
Chen L; Zheng Y; Yu K; Chen S; Wang W; Gale RP; Liu ZX; Liang Y
Leukemia; 2022 Jul; 36(7):1850-1860. PubMed ID: 35577905
[TBL] [Abstract][Full Text] [Related]
14. Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study.
Nicolini FE; Etienne G; Dubruille V; Roy L; Huguet F; Legros L; Giraudier S; Coiteux V; Guerci-Bresler A; Lenain P; Cony-Makhoul P; Gardembas M; Hermet E; Rousselot P; Amé S; Gagnieu MC; Pivot C; Hayette S; Maguer-Satta V; Etienne M; Dulucq S; Rea D; Mahon FX
Lancet Haematol; 2015 Jan; 2(1):e37-46. PubMed ID: 26687426
[TBL] [Abstract][Full Text] [Related]
15. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
Jabbour E; Short NJ; Jain N; Huang X; Montalban-Bravo G; Banerjee P; Rezvani K; Jiang X; Kim KH; Kanagal-Shamanna R; Khoury JD; Patel K; Kadia TM; Daver N; Chien K; Alvarado Y; Garcia-Manero G; Issa GC; Haddad FG; Kwari M; Thankachan J; Delumpa R; Macaron W; Garris R; Konopleva M; Ravandi F; Kantarjian H
Lancet Haematol; 2023 Jan; 10(1):e24-e34. PubMed ID: 36402146
[TBL] [Abstract][Full Text] [Related]
16. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial.
Kimura S; Imagawa J; Murai K; Hino M; Kitawaki T; Okada M; Tanaka H; Shindo M; Kumagai T; Ikezoe T; Uoshima N; Sato T; Watanabe R; Kowata S; Hayakawa M; Hosoki T; Ikeda K; Kobayashi T; Kakinoki Y; Nishimoto T; Takezako N; Shibayama H; Takaori-Kondo A; Nakamae H; Kawaguchi A; Ureshino H; Sakamoto J; Ishida Y;
Lancet Haematol; 2020 Mar; 7(3):e218-e225. PubMed ID: 31978329
[TBL] [Abstract][Full Text] [Related]
17. An update on imatinib mesylate therapy in chronic myeloid leukaemia patients in a teaching hospital in Malaysia.
Bee PC; Gan GG; Tai YT; Haris AR; Chin E; Veera SN
Singapore Med J; 2012 Jan; 53(1):57-61. PubMed ID: 22252185
[TBL] [Abstract][Full Text] [Related]
18. Patient ambassador support: Experiences of the mentorship between newly diagnosed patients with acute leukaemia and their patient ambassadors.
Nørskov KH; Overgaard D; Lomborg K; Kjeldsen L; Jarden M
Eur J Cancer Care (Engl); 2020 Nov; 29(6):e13289. PubMed ID: 32596951
[TBL] [Abstract][Full Text] [Related]
19. Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention study.
Kekäle M; Söderlund T; Koskenvesa P; Talvensaari K; Airaksinen M
J Adv Nurs; 2016 Sep; 72(9):2196-206. PubMed ID: 27113362
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.
McCormack PL; Keam SJ
Drugs; 2011 Sep; 71(13):1771-95. PubMed ID: 21902298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
